Your browser doesn't support javascript.
loading
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee, Jakrawadee; Terakura, Seitaro; Umemura, Koji; Adachi, Yoshitaka; Miyao, Kotaro; Okuno, Shingo; Takagi, Erina; Sakai, Toshiyasu; Koyama, Daisuke; Goto, Tatsunori; Hanajiri, Ryo; Hudecek, Michael; Steinberger, Peter; Leitner, Judith; Nishida, Tetsuya; Murata, Makoto; Kiyoi, Hitoshi.
Afiliación
  • Julamanee J; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan; Hematology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Terakura S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan. Electronic address: tseit@med.nagoya-u.ac.jp.
  • Umemura K; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Adachi Y; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Miyao K; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Okuno S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Takagi E; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Sakai T; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Koyama D; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Goto T; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Hanajiri R; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Hudecek M; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Steinberger P; Division for Immune Receptors and T Cell Activation, Institute of Immunology, Medical University of Vienna, Vienna, Austria.
  • Leitner J; Division for Immune Receptors and T Cell Activation, Institute of Immunology, Medical University of Vienna, Vienna, Austria.
  • Nishida T; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Murata M; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
  • Kiyoi H; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
Mol Ther ; 29(9): 2677-2690, 2021 09 01.
Article en En | MEDLINE | ID: mdl-33940156
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Antígenos CD40 / Antígenos CD19 / Antígenos CD79 / Receptores Quiméricos de Antígenos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Tailandia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Antígenos CD40 / Antígenos CD19 / Antígenos CD79 / Receptores Quiméricos de Antígenos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Tailandia